Abivax SA Sponsored ADR is a biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to help stabilize the immune response in chronic inflammatory diseases. The company’s lead program centers on obefazimod, a clinical-stage candidate being studied for inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease. Abivax SA Sponsored ADR operates as a sponsored American Depositary Receipt representing the company’s ordinary shares, giving U.S. investors access to a France-based biopharmaceutical developer. Its current work is centered on clinical research, drug development, and advancing treatments aimed at complex immune-mediated conditions. Based in Paris, Abivax SA remains positioned within the global biotechnology market as a specialist in immunology-focused therapies and late-stage clinical development.
Website7-11 boulevard Haussmann
Paris, 75009
France
ABIVAX Société Anonyme (ENXTPA:ABVX) has just paired deeper operating cash use and wider losses with fresh leadership hires and extended funding, creating a complex backdrop for anyone tracking the stock today. Recent moves have come against a tougher tape for ABIVAX Société Anonyme, with the share price down 28.78% year to date and 15.91% over 30 days, even as the 1 year total shareholder return of 16.50% and the very large 3 year total shareholder return of 446.00% point to longer term...
ABIVAX Société Anonyme (ENXTPA:ABVX) has appointed a new Chief Medical Officer and a new Chief Technical Officer. The fresh leadership roles are focused on medical strategy, product development and technical operations across Abivax SA's pipeline. The appointments are intended to support the firm's efforts around clinical programs and preparation for potential commercialization activities. The appointment of a new Chief Medical Officer and Chief Technical Officer should not be the only...
Abivax is advancing obefazimod for ulcerative colitis and Crohn’s, with recent safety concerns now largely addressed. Read more on ABVX stock here.
Abivax missed EPS estimates but beat sales in H1; shares dipped. Wedbush and Truist cut price targets to $118 and $151.
Abivax (ABVX) has an average rating of buy and mean price target of $164.20, according to analysts p
Investors talking about ABVX also mention
| # | Name | Attention |
|---|---|---|
| 1 | Nektar TherapeuticsNKTR | 0.08%+0.03 |
| 2 | Revolution Medicines, Inc.RVMD | 0.01%-0.01 |
| 3 | Apogee Therapeutics, Inc. - Common StockAPGE | 0%0 |
| 4 | uniQure N.V.QURE | 0.02%+0.01 |
| 5 | Structure Therapeutics Inc. American Depositary SharesGPCR | 0%new |
| 6 | Edgewise Therapeutics Inc.EWTX | 0%new |
| 7 | Spruce Biosciences, Inc.SPRB | 0%0 |
| 8 | Celcuity Inc.CELC | 0%0 |
| 9 | Replimune Group, Inc.REPL | 0%0 |
| 10 | Crinetics Pharmaceuticals IncCRNX | 0%new |
What share of all stock conversation is about ABVX?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0.01% -0.01 | 0.03% -0.02 | 0.03% +0.01 | 0.02% +0.01 |
Of the messages about ABVX that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | 94.34% +12.12 | 37.49% +15.35 | 33.98% -8.31 | 56.39% -31.47 | ||
| Bearish | 5.66% -12.12 | 62.51% -15.35 | 66.02% +8.31 | 43.61% +31.47 |
Of the messages about ABVX that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | 92.31% | 62.78% | 70.87% | 39.13% | ||
| Technical Analysis | 7.69% | 30.56% | 8.98% | 2.71% | ||
| Analysts | 0% | 4.44% | 16.13% | 29.34% | ||
| Macro | 0% | 2.22% | 0.22% | 26.72% | ||
| Earnings | 0% | 0% | 3.79% | 0.39% | ||
| Controversies | 0% | 0% | 0% | 1.71% |
Of the messages about ABVX, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 84.13% | 79.16% | 85.55% | 78.53% | ||
| Newcomers | 15.87% | 20.84% | 14.45% | 21.47% |